Free Trial

This company has been marked as potentially delisted and may not be actively trading.

ERYTECH Pharma (ERYP) Competitors

ERYTECH Pharma logo

ERYP vs. PLX, IKT, IZTC, JATT, CRTX, ZIVO, ALVR, FNCH, SRNE, and SQZ

Should you be buying ERYTECH Pharma stock or one of its competitors? The main competitors of ERYTECH Pharma include Protalix BioTherapeutics (PLX), Inhibikase Therapeutics (IKT), Invizyne Technologies (IZTC), JATT Acquisition (JATT), Cortexyme (CRTX), ZIVO Bioscience (ZIVO), AlloVir (ALVR), Finch Therapeutics Group (FNCH), Sorrento Therapeutics (SRNE), and SQZ Biotechnologies (SQZ). These companies are all part of the "medical" sector.

ERYTECH Pharma vs. Its Competitors

Protalix BioTherapeutics (NYSE:PLX) and ERYTECH Pharma (NASDAQ:ERYP) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.

In the previous week, Protalix BioTherapeutics' average media sentiment score of 0.00 equaled ERYTECH Pharma'saverage media sentiment score.

Company Overall Sentiment
Protalix BioTherapeutics Neutral
ERYTECH Pharma Neutral

Protalix BioTherapeutics has higher revenue and earnings than ERYTECH Pharma.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Protalix BioTherapeutics$61.95M3.20$8.31M$0.0735.57
ERYTECH Pharma$32.66M3.24-$240KN/AN/A

Protalix BioTherapeutics has a beta of -0.13, indicating that its stock price is 113% less volatile than the S&P 500. Comparatively, ERYTECH Pharma has a beta of 2.69, indicating that its stock price is 169% more volatile than the S&P 500.

16.5% of Protalix BioTherapeutics shares are held by institutional investors. Comparatively, 1.1% of ERYTECH Pharma shares are held by institutional investors. 6.5% of Protalix BioTherapeutics shares are held by company insiders. Comparatively, 1.9% of ERYTECH Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

ERYTECH Pharma has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. ERYTECH Pharma's return on equity of 0.00% beat Protalix BioTherapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Protalix BioTherapeutics-21.03% -30.89% -11.74%
ERYTECH Pharma N/A N/A N/A

Protalix BioTherapeutics currently has a consensus price target of $15.00, suggesting a potential upside of 502.41%. Given Protalix BioTherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Protalix BioTherapeutics is more favorable than ERYTECH Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Protalix BioTherapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
ERYTECH Pharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Protalix BioTherapeutics beats ERYTECH Pharma on 7 of the 12 factors compared between the two stocks.

Get ERYTECH Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for ERYP and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ERYP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ERYP vs. The Competition

MetricERYTECH PharmaBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$105.77M$357.40M$6.04B$10.49B
Dividend YieldN/AN/A5.73%4.80%
P/E RatioN/AN/A85.1927.32
Price / Sales3.24500.97516.16194.55
Price / CashN/A22.4437.5761.53
Price / Book3.883.8812.426.81
Net Income-$240K-$133.30M$3.32B$276.59M

ERYTECH Pharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ERYP
ERYTECH Pharma
N/A$3.10
flat
N/AN/A$105.77M$32.66M0.0049
PLX
Protalix BioTherapeutics
1.8964 of 5 stars
$2.57
+2.8%
$15.00
+483.7%
+123.6%$204.91M$61.95M-19.77200Gap Up
IKT
Inhibikase Therapeutics
1.2838 of 5 stars
$1.66
+2.5%
$6.50
+291.6%
+1.9%$123.70MN/A-0.626
IZTC
Invizyne Technologies
N/A$13.50
flat
N/AN/A$84.40MN/A0.0029
JATT
JATT Acquisition
N/A$4.17
+6.1%
N/A-52.7%$71.93MN/A0.003Gap Down
High Trading Volume
CRTX
Cortexyme
N/A$1.78
-8.7%
N/A+169.5%$53.67MN/A-0.6055High Trading Volume
ZIVO
ZIVO Bioscience
0.111 of 5 stars
$12.00
+2.1%
N/A-34.6%$45.80M$15.85K-2.4610Gap Up
ALVR
AlloVir
N/A$7.72
-3.9%
N/A-75.8%$38.93MN/A-0.38110High Trading Volume
FNCH
Finch Therapeutics Group
N/A$12.10
+0.6%
N/A+3.9%$19.43MN/A-1.37190
SRNE
Sorrento Therapeutics
0.8865 of 5 stars
$0.00
+12.5%
N/A+66.7%$2.48M$60.32M0.00800Gap Up
SQZ
SQZ Biotechnologies
N/A$0.03
flat
N/A+21.7%$826K$18.16M-0.011,620

Related Companies and Tools


This page (NASDAQ:ERYP) was last updated on 10/15/2025 by MarketBeat.com Staff
From Our Partners